留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

代谢相关脂肪性肝病饮食干预新策略的研究进展

叶俊钊 林衍松 钟碧慧

叶俊钊, 林衍松, 钟碧慧. 代谢相关脂肪性肝病饮食干预新策略的研究进展[J]. 临床肝胆病杂志, 2021, 37(3): 709-713. DOI: 10.3969/j.issn.1001-5256.2021.03.042
引用本文: 叶俊钊, 林衍松, 钟碧慧. 代谢相关脂肪性肝病饮食干预新策略的研究进展[J]. 临床肝胆病杂志, 2021, 37(3): 709-713. DOI: 10.3969/j.issn.1001-5256.2021.03.042
YE JZ, LIN YS, ZHONG BH. Research advances in dietary intervention in the treatment of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2021, 37(3): 709-713. DOI: 10.3969/j.issn.1001-5256.2021.03.042
Citation: YE JZ, LIN YS, ZHONG BH. Research advances in dietary intervention in the treatment of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2021, 37(3): 709-713. DOI: 10.3969/j.issn.1001-5256.2021.03.042

代谢相关脂肪性肝病饮食干预新策略的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.03.042
基金项目: 

国家自然科学基金资助项目 81870404

国家自然科学基金资助项目 81670518

国家自然科学基金资助项目 81170392

广东省科技计划项目 2013B021800290

广东省科技计划项目 2014A020212118

广东省科技计划项目 2017A020215015

详细信息
    作者简介:

    叶俊钊(1989—),男,博士后,主要从事非酒精性脂肪性肝病的基础及临床研究

    通讯作者:

    钟碧慧,zhongbh@mail.sysu.edu.cn

  • 利益冲突声明:所有作者均声明不存在利益冲突。
  • 作者贡献声明:叶俊钊负责论文撰写;林衍松协助论文修改;钟碧慧负责论文指导、审阅、经费支持。
  • 中图分类号: R575.5

Research advances in dietary intervention in the treatment of metabolic associated fatty liver disease

  • 摘要: 不良的饮食习惯是导致代谢相关脂肪性肝病(MAFLD)呈全球性流行的重要原因,而膳食模式调整更是MAFLD管理的基石。近年来大量新的治疗性膳食模式被提出并尝试应用于MAFLD的治疗,包括限制能量均衡饮食、低碳饮食、低血糖生成指数饮食、低游离糖饮食、轻断食饮食、高蛋白饮食、地中海饮食等,这些新方法在临床上应用的治疗效果不一。介绍了这些膳食治疗新策略的治疗理念、实践方法以及在国内外MAFLD人群治疗中的获益证据,为临床医生指导患者实现个体化的营养治疗提供新视角。
  • [1] ESLAM M, SARIN SK, WONG VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020. [Online ahead of print] DOI: 10.1007%2Fs12072-020-10094-2
    [2] ZHANG B, ZHAI FY, DU SF, et al. The China health and nutrition survey, 1989-2011[J]. Obes Rev, 2014, 15(Suppl 1): 2-7.
    [3] YOO ER, KIM D, VAZQUEZ-MONTESINO LM, et al. Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality[J]. Liver Int, 2020, 40(4): 815-824. DOI: 10.1111/liv.14374
    [4] ALFERINK LJ, KIEFTE-DE JONG JC, ERLER NS, et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: The rotterdam study[J]. Gut, 2019, 68(6): 1088-1098. DOI: 10.1136/gutjnl-2017-315940
    [5] CHITTURI S, WONG VW, CHAN WK, et al. The Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 2: Management and special groups[J]. J Gastroenterol Hepatol, 2018, 33(1): 86-98. DOI: 10.1111/jgh.13856
    [6] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007
    [7] SAEED N, NADEAU B, SHANNON C, et al. Evaluation of dietary approaches for the treatment of non-alcoholic fatty liver disease: A systematic review[J]. Nutrients, 2019, 11(12): 3064. DOI: 10.3390/nu11123064
    [8] ASGHARI S, ASGHARI-JAFARABADI M, SOMI MH, et al. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial[J]. J Am Coll Nutr, 2018, 37(3): 223-233. DOI: 10.1080/07315724.2017.1392264
    [9] YE J, WU Y, LI F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: Assessment using magnetic resonance imaging-derived proton density fat fraction[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819879047. http://www.ncbi.nlm.nih.gov/pubmed/31632457
    [10] MARDINOGLU A, WU H, BJORNSON E, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans[J]. Cell Metab, 2018, 27(3): 559-571. DOI: 10.1016/j.cmet.2018.01.005
    [11] AHN J, JUN DW, LEE HY, et al. Critical appraisal for low-carbohydrate diet in nonalcoholic fatty liver disease: Review and meta-analyses[J]. Clin Nutr, 2019, 38(5): 2023-2030. DOI: 10.1016/j.clnu.2018.09.022
    [12] PARKER A, KIM Y. The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with nonalcoholic fatty liver disease[J]. Metab Syndr Relat Disord, 2019, 17(8): 389-396. DOI: 10.1089/met.2019.0038
    [13] WONG VW, CHAN RS, WONG GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial[J]. J Hepatol, 2013, 59(3): 536-542. DOI: 10.1016/j.jhep.2013.04.013
    [14] HERFORTH A, ARIMOND M, ÁLVAREZ-SÁNCHEZ C, et al. A global review of food-based dietary guidelines[J]. Adv Nutr, 2019, 10(4): 590-605. DOI: 10.1093/advances/nmy130
    [15] SSCHWIMMER JB, UGALDE-NICALO P, WELSH JA, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: A randomized clinical trial[J]. JAMA, 2019, 321(3): 256-265. DOI: 10.1001/jama.2018.20579
    [16] China Expert Consensus Committee on Medical Nutrition Therapy for Overweight and Obesity. China expert consensus on medical nutrition therapy for overweight and obesity (2016)[J]. Chin J Diabetes, 2016, 8(9): 525-540. https://www.cnki.com.cn/Article/CJFDTOTAL-TNBL201610004.htm

    中国超重肥胖医学营养治疗专家共识编写委员会. 中国超重/肥胖医学营养治疗专家共识(2016年版)[J]. 中华糖尿病杂志, 2016, 8(9): 525-540. https://www.cnki.com.cn/Article/CJFDTOTAL-TNBL201610004.htm
    [17] WILKINSON MJ, MANOOGIAN E, ZADOURIAN A, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome[J]. Cell Metab, 2020, 31(1): 92-104. DOI: 10.1016/j.cmet.2019.11.004
    [18] CAI H, QIN YL, SHI ZY, et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: A randomised controlled trial[J]. BMC Gastroenterol, 2019, 19(1): 219. DOI: 10.1186/s12876-019-1132-8
    [19] de CHIARA F, URETA CHECCLLO C, RAMÓN AZCÓN J. High protein diet and metabolic plasticity in non-alcoholic fatty liver disease: Myths and truths[J]. Nutrients, 2019, 11(12): 2985. DOI: 10.3390/nu11122985
    [20] MARKOVA M, PIVOVAROVA O, HORNEMANN S, et al. Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes[J]. Gastroenterology, 2017, 152(3): 571-585. DOI: 10.1053/j.gastro.2016.10.007
    [21] SKYTTE MJ, SAMKANI A, PETERSEN AD, et al. A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: A randomised controlled trial[J]. Diabetologia, 2019, 62(11): 2066-2078. DOI: 10.1007/s00125-019-4956-4
    [22] O'KEEFE SJ. Diet, microorganisms and their metabolites, and colon cancer[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(12): 691-706. DOI: 10.1038/nrgastro.2016.165
    [23] PLAZ TORRES MC, AGHEMO A, LLEO A, et al. Mediterranean diet and NAFLD: What we know and questions that still need to be answered[J]. Nutrients, 2019, 11(12): 2971. DOI: 10.3390/nu11122971
    [24] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 64(6): 1388-1402. DOI: 10.1016/j.jhep.2015.11.004
    [25] GEPNER Y, SHELEF I, KOMY O, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content[J]. J Hepatol, 2019, 71(2): 379-388. DOI: 10.1016/j.jhep.2019.04.013
    [26] XIAO ML, LIN JS, LI YH, et al. Adherence to the dietary approaches to stop hypertension (DASH) diet is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and elderly adults[J]. Public Health Nutr, 2020, 23(4): 674-682. DOI: 10.1017/S1368980019002568
    [27] RAZAVI ZADE M, TELKABADI MH, BAHMANI F, et al. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: A randomized clinical trial[J]. Liver Int, 2016, 36(4): 563-571. DOI: 10.1111/liv.12990
    [28] ROMERO-GÓMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4): 829-846. DOI: 10.1016/j.jhep.2017.05.016
    [29] CHAN D, SO HK, HUI S, et al. Dietitian-led lifestyle modification programme for obese Chinese adolescents with non-alcoholic fatty liver disease: A randomized controlled study[J]. Int J Obes (Lond), 2018, 42(9): 1680-1690. DOI: 10.1038/s41366-018-0010-8
  • 加载中
计量
  • 文章访问数:  48
  • HTML全文浏览量:  15
  • PDF下载量:  27
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-08-17
  • 修回日期:  2020-10-22
  • 刊出日期:  2021-03-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回